

Pharmaco-disparities in heart failure: a survey of the affordability of guideline recommended therapy in 10 countries

Tauben Averbuch¹ , Meisam Esfahani^{1,2}, Rani Khatib^{3,4}, James Kayima^{5,6}, Juan Jaime Miranda^{7,8,9}, Rishi K. Wadhwa¹⁰, Faiez Zannad¹¹, Ambarish Pandey¹² and Harriette G. C. Van Spall^{1,2,13,14*}

¹Department of Medicine, McMaster University, Hamilton, Ontario, Canada; ²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; ³Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK; ⁴Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK; ⁵Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda; ⁶Department of Cardiology, Uganda Heart Institute, Kampala, Uganda; ⁷Department of Medicine, School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru; ⁸CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru; ⁹The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; ¹⁰Section of Health Policy and Equity at the Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA; ¹¹Department of Cardiovascular Disease, University of Lorraine, Vandoeuvre-Les-Nancy, France; ¹²Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA; ¹³Research Institute of St. Joseph's, Hamilton, Ontario, Canada; and ¹⁴Population Health Research Institute, Hamilton, Ontario, Canada

Abstract

Aims Heart failure with reduced ejection fraction (HFrEF) is treatable but guideline-directed medical therapy (GDMT) may not be affordable or accessible to people living with the disease.

Methods and results In this cross-sectional survey, we investigated the price, affordability, and accessibility of four pivotal classes of HFrEF GDMT: angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or angiotensin-neprilysin inhibitors (ARNI); beta-blockers; mineralocorticoid receptor antagonists (MRA); and sodium glucose co-transporter 2 inhibitors (SGLT2i). We sampled online or community pharmacies in 10 countries across a range of World Bank income groups, assessing mean 30 day retail prescription prices, affordability relative to gross national income per capita per month, and accessibility. We reported median price ratios relative to the International Reference Standard. We performed a literature review to evaluate accessibility to GDMT classes through publicly funded drug programmes in each country. HFrEF GDMT prices, both absolute and relative to the international reference, were highest in the United States and lowest in Pakistan and Bangladesh. The most expensive drug was the ARNI, sacubitril/valsartan, with a mean (standard deviation, SD) 30 day price ranging from \$11.06 (0.81) in Pakistan to \$611.50 (3.54) in United States. The least expensive drug was the MRA, spironolactone, with a mean (SD) 30 day price ranging from \$0.18 (0.00) in Pakistan to \$12.32 (0.00) in England. Affordability (SD) of quadruple therapy—ARNI, beta-blockers, MRA, and SGLT2i—was best in high-income and worst in low-income countries, ranging from 1.49 (0.00)% of gross national income per capita per month in England to 232.47 (31.47)% in Uganda. Publicly funded drug programmes offset costs for eligible patients, but ARNI and SGLT2i were inaccessible through these programmes in low- and middle-income countries. Price, affordability, and access were substantially improved in all countries by substituting ARNI for ACEi/ARB.

Conclusions There was marked variation between countries in the retail price of HFrEF GDMT. Despite higher prices in high-income countries, GDMT was more accessible and affordable than in low- and middle-income countries. Publicly funded drug programmes in lower income countries increased affordability but limited access to newer HFrEF GDMT classes. Pharmaco-disparities must be addressed to improve HFrEF outcomes globally.

Keywords Accessibility; Affordability; Cost; Equity; Heart failure; Pharmaco-disparities; Pharmacotherapy

Received: 27 January 2023; Revised: 3 May 2023; Accepted: 21 June 2023

*Correspondence to: Harriette Gillian Christine Van Spall, Population Health Research Institute, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada. Email: harriette.vanspall@phri.ca

Background

Heart failure (HF) has substantial morbidity, mortality, and healthcare expenditure.^{1,2} The global burden of HF is estimated at 56.2 million patients, with approximately half having reduced ejection fraction (HFrEF).³ Advances in the pharmacologic care of patients with HFrEF have led to improved outcomes.³ Pivotal classes of evidence-based HFrEF pharmacological treatments include angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or angiotensin-neprilysin inhibitors (ARNI); beta-blockers (BB); mineralocorticoid receptor antagonists (MRA); and sodium glucose co-transporter 2 inhibitors (SGLT2i).³ However, these four pivotal classes of guideline-directed medical therapy (GDMT) are often underutilized, depriving patients of life-saving treatments.⁴

Access to GDMT is an important barrier to HFrEF care, particularly in low and middle-income countries (LMICs) where a majority of people with HF live.² In a prior study that explored worldwide availability of medications for cardiovascular disease, significant disparities were noted between higher and lower income countries in the availability of generic ACEi and ARB in public health facilities.⁵ Among patients with a self-reported coronary event, a substantially greater proportion in high-income countries reported taking BBs (four-fold greater) and ACEi or ARBs (10-fold greater) relative to those in low-income countries, likely a reflection of disparities in access to healthcare, including pharmacological treatments.

The uptake of medications can be limited by price. In comparison with other cardiovascular diseases such as hypertension, where patients may be treated with one or two drugs, HFrEF treatment requires multiple medications with frequent need to escalate doses to optimize therapy. Prices can vary substantially, and a World Health Organization/Health Action Initiative study of countries across income levels revealed that the median price ratio (MPR; ratio of the public sector procurement price to the international reference price) of captopril, an ACEi, ranged from 0.2 to 12.7.⁶ In the same study, the affordability of generic antihypertensive medications was lower in low-income than high-income countries.⁶

Given the high and rising clinical burden of HFrEF, understanding variation in the price, affordability, and accessibility of GDMT across countries of different income levels is critically important and could inform public health and policy strategies to address treatment gaps. Therefore, in this study, we assessed the price, affordability, and accessibility of HFrEF GDMT across 10 high-, middle-, and low-income countries.

Methods

Study population

In this cross-sectional sampling survey, we aimed to include 12 low, lower-middle, upper-middle, and high-income countries, with income groups established by the World Bank.⁷ The United States, Canada, and United Kingdom were forced in the sample, with other countries chosen randomly. When data could not be obtained, we selected another country in the income level for analysis. We aimed to achieve a balance in the number of countries in each income level.

Data collection

We examined retail prices for ACEi (enalapril, ramipril, and perindopril), ARB (candesartan and valsartan), BBs (bisoprolol, carvedilol, and metoprolol), MRA (spironolactone and eplerenone), ARNI (sacubitril/valsartan), and SGLT2i (dapagliflozin and empagliflozin). For metoprolol, we included metoprolol succinate; if unavailable, we included metoprolol tartrate. The medications chosen were those with a class I indication for use in contemporary HFrEF guidelines based on a reduction in mortality or the composite of mortality and readmission.³

Online drug repositories such as those accessed via the World Health Organization do not include data on contemporary HFrEF therapies. Thus, we collected retail price data from three online pharmacies per country, chosen by convenience sampling. When online pharmacies were not available, we contacted community pharmacies in the capital city of each country via e-mail or through local investigators. Community pharmacies were limited to private pharmacies, defined as independent or chain pharmacies that charge patients for prescriptions. Public government-run or government-funded pharmacies were not included as they typically dispense medications free of charge to a limited, eligible population. Responses from community pharmacies were received between 2 November 2021 and 21 April 2022. Among the community pharmacies, we included both chain and independent pharmacies. We used the retail prices quoted for generic medications. When a generic was not available in the class, the brand-name medication was selected. Information about public programmes for drug coverage in each of the countries was obtained from literature reviews.

Statistical analysis

We reported the mean (standard deviation, SD) 30 day retail price of each drug to the patient purchasing the product before applying insurance or other subsidies. The quoted retail prices may not reflect the out-of-pocket expense to patients because of differences in insurance or government coverage. We selected the dose of each drug based on the recommended starting dose for HF. For the price of each drug, we used the lowest price quoted by the pharmacy among options listed and the price for the specified dose, rather than as a fraction of a larger dose. For example, for valsartan, the price was quoted for a 40 mg tablet, rather than half the price of an 80 mg tablet.

To assess prices relative to the international standard, we reported the MPR, defined as the price of a drug divided by its international reference price, as established by the Management Services for Health.⁸ We estimated the affordability by assessing price relative to the gross national income (GNI) per capita per month using World Bank 2021 data. We assessed whether the GDMT classes could be accessed via the online/community pharmacies or the publicly funded programmes, reporting the number and proportion (%) of pharmacies in which each drug was in stock at the time of each query. We reported all prices in USD, with conversion rates as of 21 April 2022.

Results

Countries included in survey

The analysis included four high-income (United States of America Canada, England, and Norway), three upper-middle income (Peru, South Africa, and Iran), two lower-middle income (Pakistan and Bangladesh), and one low-income country (Uganda). Syria, Togo, and Equatorial Guinea (low-income countries) were randomly and sequentially chosen for inclusion in the survey but had to be excluded as online data were not available and no responses were received from community pharmacies. Online pharmacies were available in all included countries other than Iran and Uganda, where data were obtained from community pharmacies. In South Africa, one online pharmacy and two community pharmacies were included as only one online pharmacy was available.

Price of heart failure with reduced ejection fraction guideline-directed medical therapy

The mean (SD) retail price of each HFREF drug is reported in *Table 1*. Among high-income countries, retail prices were highest in the United States, second highest in Canada, and lowest in Norway and England. The price of most HFREF med-

ications across all GDMT classes (perindopril, enalapril, valsartan, candesartan, bisoprolol, empagliflozin, dapagliflozin, and sacubitril/valsartan) were highest in the United States (*Table S1*). Among the lower income countries, prices were highest in Uganda and Peru and lowest in Pakistan and Bangladesh.

In England, there was a fixed price for each item prescribed regardless of the agent; however, for low-income patients and patients over the age of 60, the prescription fee was waived; this meant that the prices of HFREF drugs were the lowest in England regardless of pharmacy for eligible patients. The most expensive drug was sacubitril/valsartan, with the lowest 30 day mean (SD) price in Pakistan (\$11.06 [0.81]) and the highest price in the United States (\$611.50 [3.54]). The least expensive drug was spironolactone, with the lowest 30 day price quoted in Pakistan (\$0.18 [0.00]) and the highest in Canada (\$7.06 [2.36]). The least expensive ACEi was enalapril, with the lowest 30 day price in Bangladesh (\$0.35 [0.11]), and the highest in the United States (\$15.40 [1.40]). The least expensive ARB was candesartan, with the lowest 30 day price in Bangladesh (\$1.99 [0.10]), and the highest in the United States (\$52.90 [13.08]). The least expensive beta-blocker was metoprolol, with the lowest 30 day price in Bangladesh (\$0.61 [0.07]), and the highest in Canada (\$17.63 [4.79]). The least expensive SGLT2i was empagliflozin, with the lowest 30 day price in Pakistan (\$2.91 [0.20]), and the highest in the United States (\$555.93 [32.70]).

Bangladesh and Pakistan had consistently lower prices for each drug queried (*Figure 1*), while the highest prices overall were in the United States (*Table S1*).


Price relative to international reference standard

Relative to the international reference price, drug prices were highest in the United States and Canada and lowest in Pakistan and Bangladesh. The US and Canadian MPR (SD) for enalapril (50.83 [4.62] and 44.08 [14.68], respectively) and metoprolol (22.92 [5.95], 26.47 [7.19], respectively) were substantially higher than the international reference standard. By comparison, MPR in Pakistan and Bangladesh were closer to the reference standard for enalapril (1.17 [0.35] and 1.19 [0.22], respectively) and metoprolol (2.05 [0.08] and 1.82 [0.11], respectively). Among the LMICs, prices relative to reference standard were highest in Uganda, with an MPR for enalapril of 18.48 [9.80] and for metoprolol of 48.35 [1.94]. There was no international reference price available for SGLT2i and ARNI.

Price relative to monthly gross national income per capita

The lowest possible 30 day mean price [SD] as a percentage of the monthly GNI per capita of quadruple

Figure 1 The price of a 30 day prescription of select guideline-directed medical therapy for heart failure with reduced ejection fraction. All prices are in US dollars. Prices were highest in the United States and Canada. The most expensive agents were sacubitril/valsartan, dapagliflozin, and empagliflozin.



therapy—consisting of an ARNI, BB, MRA, and an SGLT2-i at the recommended starting doses was in England (1.49 [0.00]%), whereas the highest was in Uganda (232.47 [31.47]%) (Table 1). In the United States, prices relative to the monthly GNI per capita were low for BB, ACEi/ARB, and MRA [ranging from 0.05 [0.01]% to 0.29 [0.03]% for the cheapest drugs in these classes (Figure 2) but high for SGLT2i and ARNI (10.34 [0.61]% and 11.38 [0.07]%, respectively). The least affordable drug among HFREF GDMT across countries was sacubitril/valsartan, with the highest price relative to income (lowest affordability) in Uganda, Peru, and Bangladesh (147.84 [90.84]%, 21.4 [0.41]%, and 20.50 [5.00]% respectively) (Figure 3).

Guideline-directed medical therapy accessibility and coverage

With some exceptions, medications across all pivotal classes were available at the pharmacies surveyed in the 10 countries (Table 1). The least commonly available drug was ramipril (available in 20 of 27 pharmacies, 70.83%), while the most commonly available drugs were bisoprolol, valsartan, and enalapril (27 of 27 pharmacies, 100.00%).

All 10 countries had a public programme for drug coverage for eligible patients, either at the federal or provincial/state level (Table 2). Among the low-income, lower-middle, and upper-middle income countries surveyed (Pakistan, Bangladesh, Uganda, South Africa, and Peru), drug coverage was

usually limited to public pharmacies via prescriptions provided by physicians in the public system (Table 2), but the newer classes of GDMT—ARNI and SGLT2i—were not typically accessible or covered via these programmes.

In contrast, high-income countries placed no pharmacy-related restrictions on public drug coverage, although there were other restrictions. In England, there were restrictions based on provider, such that private prescriptions were not covered. In Canada and the United States, public drug coverage was offered based on age and income, such that older adults and those with low-income could access publicly funded drugs. In Canada, people eligible for publicly covered drugs were required to make a small co-payment and there was no deductible. Among high-income countries, the United States was an outlier in that older adults enrolled in Medicare part D (the drug benefit plan for Medicare) generally bore the majority of the prices of medications until the deductible was reached. After the deductible was reached, there were often tiers of coverage and a decrease in copayment after each threshold was reached; once catastrophic coverage was reached, medications were nearly or entirely covered by the insurance plan. Patients who qualified for Medicaid on the basis of income, however, bore a minority of the price, with copayment ranging from \$0.50 to \$8 per item, depending on which state the patient resided in.⁴⁶ Coverage for patients on both Medicare and Medicaid was different from either programme, reflecting the complexity of publicly funded drug programmes in the United States.

Table 1 The price and affordability of select guideline-directed medical therapies for heart failure with reduced ejection fraction worldwide

Country Pharmacy source	England (high-income)				USA (high-income)				Canada (high-income)				Norway (high-income)				Peru (upper-middle income)				
	Community		Online		Community		Online		Community		Online		Community		Online		Community		Online		
	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)
Enalapril	12.34 (0.00)	0.37 (0.00)	40.51 (0.00)	15.40 (1.40)	0.29 (0.03)	50.83 (4.62)	13.36 (4.45)	0.37 (0.12)	44.08 (14.68)	6.16 (0.04)	0.09 (0.00)	20.34 (0.13)	0.85 (0.65)	0.17 (0.13)	2.82 (2.13)	0.85 (0.65)	0.17 (0.13)	2.82 (2.13)	0.85 (0.65)	0.17 (0.13)	2.82 (2.13)
Candesartan	12.34 (0.00)	0.37 (0.00)	N/A	52.90 (13.08)	0.98 (0.24)	N/A	12.50 (1.91)	0.34 (0.05)	N/A	5.19 (1.56)	0.08 (0.02)	N/A	22.62 (7.14)	4.50 (1.42)	N/A	22.62 (7.14)	4.50 (1.42)	N/A	22.62 (7.14)	4.50 (1.42)	N/A
Bisoprolol	12.34 (0.00)	0.37 (0.00)	9.07 (0.00)	8.82 (2.88)	0.16 (0.05)	6.48 (2.11)	6.12 (3.07)	0.17 (0.08)	4.49 (2.25)	6.40 (0.03)	0.10 (0.00)	4.70 (0.02)	16.15 (9.80)	3.21 (1.95)	11.86 (7.19)	16.15 (9.80)	3.21 (1.95)	11.86 (7.19)	16.15 (9.80)	3.21 (1.95)	11.86 (7.19)
Spironolactone	12.34 (0.00)	0.37 (0.00)	20.34 (0.00)	2.51 (0.57)	0.05 (0.01)	4.13 (0.94)	7.06 (2.36)	0.19 (0.07)	11.63 (3.89)	1.91 (0.01)	0.03 (0.00)	3.14 (0.01)	3.97 (3.60)	0.79 (0.72)	6.54 (5.93)	3.97 (3.60)	0.79 (0.72)	6.54 (5.93)	3.97 (3.60)	0.79 (0.72)	6.54 (5.93)
Empagliflozin	12.34 (0.00)	0.37 (0.00)	N/A	555.93 (32.7)	10.34 (0.61)	N/A	109.47 (21.69)	3.02 (0.60)	N/A	58.02 (7.37)	0.89 (0.11)	N/A	45.16 (14.51)	8.99 (2.89)	N/A	45.16 (14.51)	8.99 (2.89)	N/A	45.16 (14.51)	8.99 (2.89)	N/A
Sacubitril/valsartan	12.34 (0.00)	0.37 (0.00)	N/A	611.50 (3.54)	11.38 (0.07)	N/A	295.23 (70.58)	8.14 (1.95)	N/A	111.69 (53.45)	1.71 (0.82)	N/A	107.52 (2.04)	21.40 (0.41)	N/A	107.52 (2.04)	21.40 (0.41)	N/A	107.52 (2.04)	21.40 (0.41)	N/A

All prices listed are in USD and represent mean (SD) price per 30 day prescription. The medications shown represent the lowest cost medication within each class.

Table 1 (continued)

Country Pharmacy source	South Africa (upper-middle income)				Pakistan (lower-middle income)				Bangladesh (lower-middle income)				Iran (lower-middle income)				Uganda (low-income)				
	Online (1/3) and community (2/3)		Online		Community		Online		Community		Online		Community		Online		Community				
	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)	Price	Price relative to GNI per capita	Median price ratio (SD)			
Enalapril	4.01 (1.60)	0.80 (0.32)	13.22 (5.28)	0.35 (0.11)	0.33 (0.10)	1.17 (0.35)	0.36 (0.07)	0.21 (0.04)	1.19 (0.22)	1.23 (0.00)	0.50 (0.00)	4.04 (0.00)	5.60 (2.97)	8.40 (4.46)	18.48 (9.80)	5.60 (2.97)	8.40 (4.46)	18.48 (9.80)	5.60 (2.97)	8.40 (4.46)	18.48 (9.80)
Candesartan	15.54 (2.86)	3.10 (0.57)	N/A	1.99 (0.35)	1.88 (0.33)	N/A	1.99 (0.10)	1.18 (0.06)	N/A	N/A	N/A	N/A	14.56 (5.44)	21.84 (8.16)	N/A	14.56 (5.44)	21.84 (8.16)	N/A	14.56 (5.44)	21.84 (8.16)	N/A
Bisoprolol	0.60 (0.60)	0.42 (0.12)	0.44 (0.44)	0.44 (0.11)	0.42 (0.10)	0.33 (0.08)	0.33 (0.11)	0.18 (0.06)	1.46 (0.08)	1.74 (0.03)	0.71 (0.01)	1.28 (0.02)	5.88 (0.49)	8.82 (0.730)	4.32 (0.36)	5.88 (0.49)	8.82 (0.730)	4.32 (0.36)	5.88 (0.49)	8.82 (0.730)	4.32 (0.36)
Spironolactone	2.11 (0.70)	0.42 (0.14)	3.48 (1.15)	0.18 (0.00)	0.17 (0.00)	0.30 (0.01)	0.83 (0.05)	0.49 (0.03)	1.37 (0.07)	1.28 (0.00)	0.52 (0.00)	1.2 (0.00)	3.50 (1.49)	5.25 (2.23)	5.76 (2.45)	3.50 (1.49)	5.25 (2.23)	5.76 (2.45)	3.50 (1.49)	5.25 (2.23)	5.76 (2.45)
Empagliflozin	31.42 (7.08)	6.27 (1.41)	N/A	2.91 (0.20)	2.75 (0.19)	N/A	7.24 (2.20)	4.28 (1.30)	N/A	23.29 (0.00)	9.44 (0.00)	N/A	49.00 (31.75)	73.50 (47.62)	N/A	49.00 (31.75)	73.50 (47.62)	N/A	49.00 (31.75)	73.50 (47.62)	N/A
Sacubitril/valsartan	91.10 (46.53)	18.19 (9.29)	N/A	11.06 (0.81)	10.45 (0.76)	N/A	33.92 (8.46)	20.05 (5.00)	N/A	23.43 (0.00)	9.50 (0.00)	N/A	98.56 (60.56)	147.84 (90.84)	N/A	98.56 (60.56)	147.84 (90.84)	N/A	98.56 (60.56)	147.84 (90.84)	N/A

All prices listed are in USD and represent mean (SD) price per 30 day prescription. The medications shown represent the lowest cost medication within each class.

Figure 2 The price of a 30 day prescription of heart failure with reduced ejection fraction pharmacotherapy relative to the GNI per capita per month. The proportional price of heart failure with reduced ejection fraction pharmacotherapy was highest in lower-middle and upper-middle income countries. The most expensive medications relative to GNI per capita per month were empagliflozin, dapagliflozin, and sacubitril/valsartan. GNI, gross national income.





Figure 3 The price of a 30 day supply of triple and quadruple therapy as a percentage of GNI per capita per month. Triple therapy refers to the combination of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker (whichever is less expensive), beta-blocker, and mineralocorticoid receptor antagonists. Quadruple therapy refers to the combination of angiotensin-neprilysin inhibitors, beta-blocker, mineralocorticoid receptor antagonists, and sodium glucose co-transporter 2. GNI, gross national income.



In high-income countries, the covered formulary included all pivotal HFrEF drugs, whereas low-income and middle-income countries omitted eplerenone, SGLT2i and

ARNI. England was the only high-income country where the price of the medication was entirely covered with a dispensing fee. The price of medications to the English government

Table 2 Public coverage of guideline-directed medical therapy by country

Country	Publicly-funded drug coverage (yes/no)	Who qualifies	Degree of coverage	Which HFREF drugs are covered
Canada	Yes	Province dependent, generally only low-income (variably defined) and patients >65	Full for eligible patients with variable co-pay	All
England	Yes	All patients. Patients <60 and those receiving income support are exempt from dispensing fees	Full coverage with a \$12.34 dispensing fee per item. Patients can pre-pay for 3 months (\$36.62) or 12 months (\$130.85)	All
Norway	Yes	All patients	15% of medication cost is paid out of pocket	All
USA	Yes	Medicare: Patients >65, or with disabilities and/or ESRD Medicaid: Low-income patients up to 133% of the federal poverty level	Medicare: Variable, increases once deductible paid, up to 75% once catastrophic coverage limit reached Medicaid: full coverage with variable copay	All
Iran	Yes	Government employees, Residents in rural areas and cities less than 20,000 population, Self-employed, Students, patients with disabilities, families with injured persons during the war, private sector employees, and Military personnel and their families	Coverage of 70–90% of the cost of medication	Enalapril, valsartan, metoprolol, and spironolactone
Peru	Yes	EsSalud: All patients who are formally employed Seguro Integral de Salud: Very low-income patients	EsSalud: Full coverage with variable copay Seguro Integral de Salud: Full coverage with no co-pay	EsSalud: Enalapril, carvedilol, bisoprolol, valsartan, and spironolactone
South Africa	Yes	Patients who use public health facilities	Full if through a public health facility	Enalapril, carvedilol, and spironolactone
Bangladesh	Yes	All patients using public clinics and the outpatient department of public hospitals	Full coverage without co-pay, however informal payments often required	All essential medicines list (2008): enalapril, spironolactone
Pakistan	Yes	All patients using public primary health clinics	Full coverage without co-pay	Enalapril, bisoprolol, and spironolactone
Uganda	Yes	All patients using public health facilities	Full coverage without co-pay	Enalapril, candesartan, carvedilol, bisoprolol, and spironolactone

Sources: references (9–45).

ESRD, end-stage renal disease; HFREF, heart failure with reduced ejection fraction.

EsSalud refers to Seguro Social de Salud del Peru, the social health insurance of Peru.


Seguro Integrable de Salud refers to the comprehensive health insurance program of Peru.

was higher than price to patients for SGLT2i and ARNI (Table 1) but lower than the price to patients for ACEi, ARB, BBs, and MRAs. By contrast, in Norway, the price to the government was greater than the price to the patient for all agents in our study, with 85% of the price of all medications covered (Table 2).

Discussion

In this cross-sectional sampling survey of 10 countries across the world, we found variation in pricing relative to the international standard and pharmaco-disparities in access to and

affordability of GDMT, particularly with newer classes (Central Illustration). The retail price of HFREF pharmacotherapy and price relative to the international standard were highest in high-income countries, most notably in the United States, and lowest in low-income and lower-middle income countries. However, price relative to the GNI per capita was highest (i.e. affordability was lowest) in lower income countries, most notably, Uganda. While the four pivotal GDMT classes were available in private pharmacies in all the countries surveyed, newer classes (including ARNI and SGLT2i) were not covered by publicly funded programmes in LMIC. Our study adds insight into the global variations in the price of contemporary HFREF medications and the pharmaco-disparities in access and affordability across the world.



CENTRAL ILLUSTRATION: Factors that influence the price of HFREF pharmacotherapy. In our study, we found that while the price of HFREF pharmacotherapy was highest in high-income countries, the affordability was worse in middle- and low-income countries. Several factors influence the affordability of medications, including procurement costs, purchasing power, price regulation, domestic manufacture, and the availability of public and generic options. Potential solutions to high drug costs include centralized procurement, price negotiation as a criterion for approval, transparency in drug pricing, and federal insurance/subsidies to reduce patient costs.

Price

The price of HFREF pharmacotherapy relative to the international standard was higher in high-income countries, with the highest retail prices in the United States. The high price of pharmacotherapy in the United States relative to other countries may be related to the regulatory framework regarding drug pricing and the size and negotiating strength of each payer.⁴⁷ The system by which drugs are priced is opaque, involving multiple parties with competing interests: pharmaceutical manufacturers; public and private insurers; pharmacy benefit managers, and pharmacies.⁴⁸ Federal drug pricing legislation is largely absent, and Medicare has historically been forbidden from negotiating prices with drug manufacturers and implementing a price structure as a condition for reimbursement.⁴⁹ The passage of the Inflation Reduction Act now allows Medicare to negotiate prices for 10 medications by 2026; however, it is not yet known whether this will apply to HF GDMT.⁵⁰ In addition, there are multiple avenues for costs to be passed back to the patient, including insurance authorizations, deductibles, co-insurance (a proportion of the drug list price), and co-payments (a fixed price per prescription). The high prices in the United States may allow pharmaceutical companies to recover their investments.⁴⁸ It is possible that the high prices in the United States subsidize the price of medications in other countries⁴⁸ but translate to disparities within the United States.

Several factors influence price variation across countries (Central Illustration). Similar to high-income countries other than the United States, Peru, South Africa, Bangladesh, Pakistan and Iran have federal regulation on drug pricing^{51–55}; in contrast, drug pricing is not regulated in Uganda and procurement of medications involves multiple stakeholders, leading to low purchasing power in Uganda.⁵⁶ The domestic manufacture of drugs is another factor, explaining the lower prices in Pakistan and Bangladesh rel-

ative to Peru, South Africa, and Uganda.²¹ The domestic market share is 80% in Bangladesh, and only 10% in Uganda.^{57,58} Governments could promote domestic drug manufacture by subsidizing the cost of imported pharmaceutical ingredients and lifting import restrictions, which remain barriers to affordable domestic production.⁵⁹ Another barrier is patent law, particularly for agents without a generic equivalent (e.g. ARNI and SGLT2is); this can be mitigated by patent pooling, whereby sub-licences are granted to manufacturers in low- and middle-countries to allow manufacture and sale without royalties. The Medicines Patent Pool, a United Nations-backed organization, has led to significant reductions in drug prices for HIV and hepatitis C.⁶⁰

Affordability and accessibility

Affordability of contemporary HFREF quadruple GDMT at retail pricing was greatest in England, Norway, and Canada, and worst in Uganda, Peru, Bangladesh, and South Africa; and improved with use of an ACEi/ARB instead of ARNI in all countries sampled. Our findings are consistent with studies of ischemic heart disease that demonstrated greater affordability of medication (price <20% of the household income) in high versus lower income countries.⁶¹ The lower affordability of HFREF pharmacotherapy in LMICs may contribute to their lower uptake; in a global registry, patients in lower-middle income countries were less likely than those in high-income countries to use an ACEi or ARB, BB, or MRA 6 months following hospitalization for HFREF.⁶²

Public or private drug insurance may improve affordability, but accessibility to newer classes via these programmes remains a limitation in lower income countries. In a study in Peru, 26% of patients covered through the public drug plan for low-income patients had to incur out of pocket expenses for medications.⁹ Public facilities in both Pakistan and Bangladesh were found to have poor availability of essential medications, with frequent stock-outs and reliance on private pharmacies.^{63,64} Similarly, a study of Ugandan rural households found that 77% of respondents preferred using private health facilities due to unavailability of medications via public health services.⁶⁵ As a result, Ugandan patients face high out-of-pocket costs. South Africa has an established public healthcare network that is constrained by medication shortages and inadequate staffing.⁶⁶ As an alternative to two-tiered systems of pharmacotherapy, federal/state governments could subsidize GDMT in both public and private settings, as is being considered in Pakistan⁶⁷; such a model could also be applied to outpatient prescriptions. In the United States, insurance and Medicaid plan D may reduce out of pocket expenses, but the need for prior authorizations or approvals and complex policies regarding coverage, deductibles, and copayments

limit access to GDMT and shift costs to patients. Programmes that include vouchers, discounts, and copayment cards can improve affordability and medication adherence.⁶⁸ Pragmatic clinician-level solutions such as drug or class substitutions, prescribing a larger dose that can then be divided to minimize the daily price and providing free samples, may also be considered in select cases.⁶⁹

The affordability of HFREF GDMT is important not only to patients but also to healthcare systems. In healthcare systems where pharmacotherapy is subsidized, the prices borne by patients may be far lower than the prices to the healthcare system. For example, in England, the mean (SD) 30 day price charged to patients for empagliflozin, dapagliflozin, and sacubitril/valsartan was \$12.35 (0.00), whereas the prices charged to pharmacies by their suppliers were 4 to 10 times higher (Table 1), although this amount was later reimbursed to the pharmacy by the National Health Service.⁷⁰ Measures such as price controls, domestic manufacture, and centralized procurement may facilitate sustainability. One potential avenue for governments to reduce or limit pharmaceutical expenditures is to require a cost-effectiveness analysis prior to approval, as is done in some countries.⁷¹ Countries in which the federal government procures medications may be better able to negotiate pricing to ensure cost-effectiveness. Cost-sharing agreements between the government and manufacturers may also improve the affordability of HF therapy for both governments and patients.

Limitations

Our sample was restricted to 10 countries. We only listed prices for the lowest doses of each agent and our analysis focused on retail prices paid by patients; the prices do not represent the cost incurred by pharmacies or amounts paid by patients enrolled in publicly funded or private insurance programmes. While we used data from online pharmacies, the additional physical pharmacies surveyed in each country were from the capital city; prices may have been higher and access to drugs poorer in rural locales. Our survey of prices was limited to private pharmacies, as price data from public pharmacies were unavailable. Although we adjusted for the dose of medication in our cost analysis, not all pharmacies queried offered the same dosages of medication. Our analysis of affordability relied on the GNI per capita rather than household or disposable income as an established reference. Our analysis may overestimate affordability as we could not account for patients' non-medical expenses or disposable income. Low-income countries were underrepresented within our study, with only one low-income country included (Uganda), due to unavailability of data. Lastly, our results are reflective of cost and affordability at the time of sampling.

Conclusions

The retail price of HF medication varies markedly between countries, with greater accessibility and affordability in high-income countries despite higher prices. Among high-income countries, prices were the highest in the United States. Public programmes increased affordability of GDMT but limited access to newer HFREF classes in low- and lower-middle income countries. In LMICs, a 30 day supply of contemporary quadruple HFREF GDMT at starting doses cost one-quarter to twice the GNI per capita per month. At current prices, ACEi/ARBs may represent greater value than ARNI particularly in low resource settings. The variation in price of HFREF therapy is likely multifactorial but culminates in pharmaco-disparities that must be reduced to improve uptake of effective therapies and improve HFREF outcomes globally.

Acknowledgements

The authors would like to thank Ms. Janeth Tenorio for her review of the initial draft of this manuscript.

References

1. Van Spall HGC, Lee SF, Xie F, Oz UE, Perez R, Mitoff PR *et al.* Effect of patient-centered transitional care services on clinical outcomes in patients hospitalized for heart failure: the PACT-HF randomized clinical trial. *JAMA* 2019;**321**:753–761.
2. Wei S, Miranda JJ, Mamas MA, Zühlke LJ, Kontopantelis E, Thabane L, Van Spall HGC. Sex differences in the etiology and burden of heart failure across country income level: analysis of 204 countries and territories 1990–2019. *Eur Heart J - Qual Care Clin Outcomes* 2022;qcac088.
3. McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N *et al.* CHFS heart failure guide/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. *Can J Cardiol* 2021;**37**:531–546.
4. Van Spall HGC, Fonarow GC, Mamas MA. Underutilization of guideline-directed medical therapy in heart failure. *J Am Coll Cardiol* 2022;**79**:2214–2218.
5. Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P *et al.* Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, Price, availability, and affordability. *J Am Heart Assoc* 2020;**9**:e015302.
6. van Mourik MSM, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. *BMC Cardiovasc Disord* 2010;**10**:25.
7. World Bank Country and Lending Groups [Internet]. World Bank; 2021 Oct [cited 2021 Oct 18] p. 1. Available from: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups>. Accessed 18 Oct 2021.
8. International Medical Products Price Guide [Internet]. Management sciences for health; [cited 2021 Oct 22]. Available from: <https://www.msh.org/resources/international-medical-products-price-guide>. Accessed 22 Oct 2021.
9. Espinoza G. *The effects of Seguro Integral de Salud on healthcare utilization, health-care out-of-pocket expenditures, and health in Peru*. University of Minnesota; 2021.
10. *Standard Treatment Guidelines and Essential Medicines List for South Africa*. Department of Health; 2020.
11. Clement F, Memedovich KA. Drug coverage in Canada: gaps and opportunities. *J Psychiatry Neurosci JPN* 2018;**43**:148–150.
12. *Formulary*. Ministry of Health and Long-Term Care; [2022]. Available from: <https://www.formulary.health.gov.on.ca/formulary/>
13. *List of medications*. Régie de l'assurance maladie; 2022. Available from: <https://www.ramq.gouv.qc.ca/en/media/13541>
14. *Interactive drug benefit list*. Alberta Ministry of Health; 2022 [cited 2022 Jul 8]. Available from: <https://idbl.ab.bluecross.ca/idbl/load.do>
15. *Pharmacare Formulary Search*. Ministry of Health of British Columbia; 2022 [cited 2022 Jul 8]. Available from: <https://pharmacareformularysearch.gov.bc.ca/Search.xhtml>
16. *Saskatchewan Formulary Bulletin Update to the 62nd Edition of the Saskatchewan Formulary*. Saskatchewan Ministry of Health; 2017 [cited 2022 Jul 8]. Available from: <https://formulary.drugplan.ehealthsask.ca/Bulletins/Bulletin-0164-Apr-2017.pdf>
17. *Formulary*. Nova Scotia Department of Health; 2022 [cited 2022 Jul 8]. Available from: <https://novascotia.ca/dhw/pharmacare/documents/formulary.pdf>
18. *Search the NLPDP Drug Product Database*. Health and Community Services; 2022 [cited 2022 Jul 8]. Available from: <https://www.health.gov.nl.ca/health/prescription/newformulary.asp>
19. *New Brunswick Drug Plans Formulary*. Medavie Blue Cross; 2022 [cited 2022 Jul 8]. Available from: <https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDDrugPlan/NewBrunswickDrugPlansFormulary.pdf>
20. *PEI Pharmacare Formulary*. Health PEI; 2022 [cited 2022 Jul 8]. Available from: <https://www.princeedwardisland.ca/>

Conflict of interest

HGCV receives funding from the Canadian Institutes of Health Research. The authors have no conflicts of interest to disclose.

Funding

None.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. The price of heart failure guideline-directed medical therapy in 10 countries.

- sites/default/files/publications/pei_pharmacare_formulary.pdf
21. Manitoba Drug Benefits Formulary. Health and Seniors Care; 2022 [cited 2022 Jul 8]. Available from: https://residents.gov.mb.ca/forms.html?d=details&pub_id=10541&filter_keyword=drug%20benefits
 22. *Your Guide to Medicare Prescription Drug Coverage*. Centers for Medicare and Medicaid Services; 2021.
 23. *Determining eligibility for Medicaid*. Centers for Medicare and Medicaid Services; [cited 2022 Jul 4]. Available from: <https://www.medicaid.gov/medicaid/eligibility/index.html>
 24. *Cost Sharing Out of Pocket Costs*. Centers for Medicare and Medicaid Services; [cited 2022 Jul 4]. Available from: <https://www.medicaid.gov/medicaid/cost-sharing/cost-sharing-out-pocket-costs/index.html>
 25. *Explore your medicare coverage options*. Centers for Medicare and Medicaid Services; 2022. Available from: <https://www.medicare.gov/plan-compare/#/?year=2022&lang=en>
 26. *Who can get free prescriptions?* National Health Service; 2020 [cited 2022 Jul 4]. Available from: <https://www.nhs.uk/nhs-services/prescriptions-and-pharmacies/who-can-get-free-prescriptions/>
 27. *NHS prescription charges*. National Health Service; [cited 2022 Jul 4]. Available from: <https://www.nhs.uk/nhs-services/prescriptions-and-pharmacies/nhs-prescription-charges/>
 28. *British National Formulary*. National Institute for Health and Care Excellence; 2022 [cited 2022 Jul 8]. Available from: <https://bnf.nice.org.uk>
 29. Cornejo E. *Medicine prices, availability, affordability and price components in Peru*. Health Action International Latin American Coordination Office; 2007.
 30. Espinoza G. *The Effects of Seguro Integral de Salud on Healthcare Utilization, Healthcare Out-of-pocket Expenditures, and Health in Peru*. University of Minnesota; 2021.
 31. *Petitorio Farmacologico De EsSalud*. Ministry of Labour and Transportation; 2017 [cited 2022 Jul 4]. Available from: http://www.essalud.gob.pe/ietsi/pdfs/normas/compilacion_petitorio_farmacologico_ESSALUD_2017.pdf
 32. Twikirize JM, O'Brien C. Why Ugandan rural households are opting to pay community health insurance rather than use the free healthcare services. *Int J Soc Welf* 2012;**21**:66-78.
 33. *Essential medicines and health supplies list for Uganda*. Ministry of Health; 2016.
 34. Mannan M. Access to public health facilities in Bangladesh: a study on facility utilisation and burden of treatment. *Bangladesh Dev Stud*. 2013;**36**:25-80. doi:10.1503/jpn.180051
 35. *Medicines in health care delivery: Bangladesh*. World Health Organization, Regional Office for South East Asia; 2014 [cited 2022 Jul 10]. Available from: https://cdn.who.int/media/docs/default-source/searo/hsd/edm/csa-bangladesh-situational-analysis-2015.pdf?sfvrsn=941031d3_2
 36. Pavel MS, Chakrabarty S, Gow J. Cost of illness for outpatients attending public and private hospitals in Bangladesh. *Int J Equity Health* 2016;**15**:167. doi:10.1186/s12939-016-0458-x
 37. *Directorate General of Drug Administration. Bangladesh National Formulary*. Ministry of Health and Family Welfare; 2019.
 38. *List of essential drugs*. Ministry of Health and Family Welfare; 2008.
 39. MedCOI. *Country Policy and Information Note Pakistan: Medical and healthcare provisions*. UK Home Office; 2020 [cited 2022 Jul 10]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/924029/Pakistan_Medical_and_Healthcare_issues_-_CPIN.pdf
 40. Zaidi S, Idrees N, Riaz A. *Primary health care systems (PRIMASYS): comprehensive case study from Pakistan*. World Health Organization; 2017.
 41. *Drug Regulatory Authority of Pakistan. National Essential Medicines List*. Ministry of National Health Services; 2018 [cited 2022 Jul 10]. Available from: <https://phkh.nhsrpk/sites/default/files/2019-06/National%20Essential%20Medicines%20List%202018.pdf>
 42. Doshmangir L, Bazayr M, Rashidian A, Gordeev VS. Iran health insurance system in transition: equity concerns and steps to achieve universal health coverage. *Int J Equity Health* 2021;**20**:37. doi:10.1186/s12939-020-01372-4
 43. *Essential Medicine List*. Food and Drug Administration of Iran; 2009 [cited 2022 Jul 10]. Available from: https://health.sbm.ac.ir/uploads/22_5907_1562565256170_drug_list.pdf
 44. Saunes IS, Karanikolos M, Sagan A. Norway: health system review. *Health Syst Transit* 2020;**22**:1-163.
 45. *Norwegian Prescription Database*. Norwegian Institute of Public Health; 2021 [cited 2022 Jul 10]. Available from: <http://www.norpd.no/>
 46. *Medicaid benefits: prescription drugs [Internet]*. Kaiser Family Foundation; 2018. Available from: <https://www.kff.org/medicaid/state-indicator/prescription-drugs/>. Accessed 08 Jul 2022.
 47. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. *JAMA* 2016;**316**:858-871.
 48. Augustine N. R., Madhavan G., Nass S. J., National Academies of Sciences, Engineering, and Medicine (U.S.), National Academies of Sciences, Engineering, and Medicine (U.S.), National Academies of Sciences, Engineering, and Medicine (U.S.), eds. *Making medicines affordable: a national imperative*. Washington, DC: National Academies Press; 2018 206 p. (Consensus study report).
 49. Subpart 2—Prescription Drug Plans; PDP Sponsors; Financing [Internet]. Social Security Administration; 2003 [cited 2022 Jul 7]. Available from: Subpart 2—Prescription Drug Plans; PDP Sponsors; Financing.
 50. Inflation reduction act 5 of 2022. Committee on Finance; 2022.
 51. Zaboli P, Hashemi-Meshkini A, Varmaghani M, Gholami H, Vazirian I, Zekri HS *et al.* Pharmaceutical laws and regulations in Iran: an overview. *J Res Pharm Pract* 2016;**5**:155-161.
 52. Lee KS, Shahidullah A, Zaidi STR, Patel RP, Ming LC, Tariq MH *et al.* The crux of the medicine prices' controversy in Pakistan. *Front Pharmacol* 2017;**8**:504.
 53. Kasonde L, Tordrup D, Naheed A, Zeng W, Ahmed S, Babar ZUD. Evaluating medicine prices, availability and affordability in Bangladesh using World Health Organisation and health action international methodology. *BMC Health Serv Res* 2019;**19**:383.
 54. Moodley R, Suleman F. The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014. *PLoS ONE* 2019;**14**:e0219690.
 55. Cornejo E. *Medicine prices, availability, affordability and price components in Peru*. Health Action International Latin American Coordination Office; 2007.
 56. Lugada E, Komakech H, Ochola I, Mwebaze S, Olowo Oteba M, Okidi LD. Health supply chain system in Uganda: current issues, structure, performance, and implications for systems strengthening. *J Pharm Policy Pract* 2022;**15**:14.
 57. Kaplan W. *Local production and access to medicines in low- and middle-income countries: A literature review and critical analysis*. World Health Organization; 2011.
 58. Brhlikova P, Maigetter K, Murison J, Agaba AG, Tusiimire J, Pollock AM. Registration and local production of essential medicines in Uganda. *J Pharm Policy Pract* 2020;**13**:31.
 59. Olyaaeemanesh A, Jaafari-pooyan E, Abdollahiasl A, Davari M, Mousavi SM, Delpasand M. Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis. *Health Res Policy Syst*. 2021;**19**:150.
 60. Burrone E, Gotham D, Gray A, de Joncheere K, Magrini N, Martei YM *et al.* Patent pooling to increase access to essential medicines. *Bull World Health Organ* 2019;**97**:575-577.
 61. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K *et al.* Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. *Lancet* 2016;**387**:61-69.

62. Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W *et al.* Correction to: post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. *Lancet Glob Health* 2020;**8**:e1001.
63. Mannan M. Access to public health facilities in Bangladesh: a study on facility utilisation and burden of treatment. *Bangladesh Dev Stud* 2013;**36**:25–80.
64. Zaidi S, Bigdeli M, Aleem N, Rashidian A. Access to essential medicines in Pakistan: policy and health systems research concerns. Ed. Meara JG, *PLoS ONE* 2013;**8**:e63515.
65. Twikirize JM, O'Brien C. Why Ugandan rural households are opting to pay community health insurance rather than use the free healthcare services. *Int J Soc Welf* 2012;**21**:66–78.
66. Maphumulo WT, Bhengu BR. Challenges of quality improvement in the healthcare of South Africa post-apartheid: a critical review. *Curationis [Internet]* 2019;**42**:1901. Available from: <http://www.curationis.org.za/index.php/curationis/article/view/1901>
67. About the program [Internet]. Sehat Sahulat Program; 2022. [cited 2022 Jul 22]. Available from: <https://www.pmhealthprogram.gov.pk/about-us/>. Accessed 22 Jul 2022.
68. Hung A, Blalock DV, Miller J, McDermott J, Wessler H, Oakes MM *et al.* Impact of financial medication assistance on medication adherence: a systematic review. *J Manag Care Spec Pharm* 2021;**27**:924–935.
69. Faridi KF, Dayoub EJ, Ross JS, Dhruva SS, Ahmad T, Desai NR. Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure. *J Am Coll Cardiol* 2022;**79**:2516–2525.
70. Sending in your claim [Internet]. NHS Business Services Authority; [cited 2022 Jul 21]. Available from: <https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/submitting-prescriptions/sending-your-claim>. Accessed 21 Jul 2022.
71. Walker S, Palmer S, Sculpher M. The role of NICE technology appraisal in NHS rationing. *Br Med Bull* 2007;**81**–**82**:51–64.